A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 48/00 (2006.01) A61K 31/445 (2006.01) A61K 31/5375 (2006.01) A61K 31/7032 (2006.01) A61K 31/7088 (2006.01) A61K 38/43 (2006.01) A61P 3/00 (2006.01) A61P 9/10 (2006.01) A61P 25/00 (2006.01) A61P 25/08 (2006.01) A61P 25/16 (2006.01) A61P 25/28 (2006.01)
Patent
CA 2368814
The present invention relates to the treatment of conditions such as Niemann- Pick C storage disease, Alzheimer's disease, epilepsy, stroke and Parkinson's disease, and in particular to the use of inhibitors of glucosylceramide synthesis in such treatment. Preferred inhibitors of glucosylceramide synthesis are imino sugar-structured, and include N-butyldeoxynojirimycin (NB-DNJ), N-butyldeoxygalactonojirimycin (NB-DGJ) and N-nonyldeoxynojirimycin (NN-DNJ).
La présente invention a pour objet le traitement de maladies telles que la maladie de Niemann-Pick de type C, la maladie d'Alzheimer, l'épilepsie, des accidents vasculaires cérébraux et la maladie de Parkinson. Elle a pour objet en particulier l'utilisation d'inhibiteurs de la synthèse du glucosylcéramide dans un tel traitement. Les inhibiteurs préférés de la synthèse du glucosylcéramide présentent une structure d'iminosucre et comprennent la N-butyldésoxynojirimycine (NB-DNJ), la N-butyldésoxygalactonojirimycine (NB-DGJ) et la N-nonyldésoxynojirimycine (NN-DNJ).
Holt Gordon D.
Walkley Steven
Actelion Pharmaceuticals Ltd
Oxford Glycosciences (uk) Limited
Smart & Biggar
LandOfFree
Use of glucosylceramide synthesis inhibitors in therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of glucosylceramide synthesis inhibitors in therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of glucosylceramide synthesis inhibitors in therapy will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2071099